表紙
市場調査レポート

NovaRx Corporationの製品パイプライン分析

NovaRx Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321967
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
NovaRx Corporationの製品パイプライン分析 NovaRx Corporation - Product Pipeline Review - 2015
出版日: 2015年07月15日 ページ情報: 英文 24 Pages
概要

NovaRx Corporationは米国に本社を置くバイオ製薬企業で、癌治療用の細胞ワクチンを創薬・開発・販売しています。

当レポートでは、NovaRx Corporation における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

NovaRx Corporation の基本情報

  • NovaRx Corporation の概要
  • 主要情報
  • 企業情報

NovaRx Corporation :R&Dの概要

  • 主な治療範囲

NovaRx Corporation :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

NovaRx Corporation :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

NovaRx Corporation :薬剤プロファイル

  • belagenpumatucel-L
  • ranagengliotucel-T
  • TSC-08D

NovaRx Corporation :パイプライン分析

  • 投与経路別
  • 分子タイプ別

NovaRx Corporation :最新のパイプライン情報

NovaRx Corporation :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07341CDB

Summary

Global Markets Direct's, 'NovaRx Corporation - Product Pipeline Review - 2015', provides an overview of the NovaRx Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NovaRx Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of NovaRx Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of NovaRx Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the NovaRx Corporation's pipeline products

Reasons to buy

  • Evaluate NovaRx Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of NovaRx Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the NovaRx Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of NovaRx Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of NovaRx Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of NovaRx Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NovaRx Corporation Snapshot
    • NovaRx Corporation Overview
    • Key Information
    • Key Facts
  • NovaRx Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • NovaRx Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • NovaRx Corporation - Pipeline Products Glance
    • NovaRx Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • NovaRx Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • NovaRx Corporation - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • NovaRx Corporation - Drug Profiles
    • ranagengliotucel-T
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ES-22M
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Panvaxal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TSC-08D
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NovaRx Corporation - Pipeline Analysis
  • NovaRx Corporation - Pipeline Products by Target
  • NovaRx Corporation - Pipeline Products by Route of Administration
  • NovaRx Corporation - Pipeline Products by Molecule Type
  • NovaRx Corporation - Pipeline Products by Mechanism of Action
  • NovaRx Corporation - Dormant Projects
  • NovaRx Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NovaRx Corporation, Key Information
  • NovaRx Corporation, Key Facts
  • NovaRx Corporation - Pipeline by Indication, 2015
  • NovaRx Corporation - Pipeline by Stage of Development, 2015
  • NovaRx Corporation - Monotherapy Products in Pipeline, 2015
  • NovaRx Corporation - Phase II, 2015
  • NovaRx Corporation - Preclinical, 2015
  • NovaRx Corporation - Unknown, 2015
  • NovaRx Corporation - Pipeline by Target, 2015
  • NovaRx Corporation - Pipeline by Route of Administration, 2015
  • NovaRx Corporation - Pipeline by Molecule Type, 2015
  • NovaRx Corporation - Pipeline Products by Mechanism of Action, 2015
  • NovaRx Corporation - Dormant Developmental Projects,2015

List of Figures

  • NovaRx Corporation - Pipeline by Top 10 Indication, 2015
  • NovaRx Corporation - Pipeline by Stage of Development, 2015
  • NovaRx Corporation - Monotherapy Products in Pipeline, 2015
  • NovaRx Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top